<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.26733.005</object-id><label>Table 1.</label><caption><p>Clinico-pathological correlation of NFATc2 in NSCLC patients.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.26733.005">http://dx.doi.org/10.7554/eLife.26733.005</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4"><bold>A. Clinico-pathological correlation of NFATc2 in NSCLC patients</bold></th></tr><tr><th/><th colspan="2">NFATc2</th><th/></tr><tr><th>Clinico-pathological variables</th><th>Low</th><th>High</th><th>P value</th></tr></thead><tbody><tr><td>Gender</td><td/><td/><td/></tr><tr><td>&#8195;Female</td><td>22</td><td>11</td><td>0.328</td></tr><tr><td>&#8195;Male</td><td>39</td><td>30</td><td/></tr><tr><td>Age (Years)</td><td/><td/><td/></tr><tr><td>&#8195;&#8804;65</td><td>36</td><td>24</td><td>0.961</td></tr><tr><td>&#8195;&gt;65</td><td>25</td><td>17</td><td/></tr><tr><td>Smoking history</td><td/><td/><td/></tr><tr><td>&#8195;Non-smoker</td><td>32</td><td>24</td><td>0.545</td></tr><tr><td>&#8195;Smoker</td><td>29</td><td>17</td><td/></tr><tr><td>Differentiation</td><td/><td/><td/></tr><tr><td>&#8195;Well to moderate</td><td>45</td><td>21</td><td>0.019*</td></tr><tr><td>&#8195;Poor</td><td>16</td><td>20</td><td/></tr><tr><td>Histologic type</td><td/><td/><td/></tr><tr><td>&#8195;Adenocarcinoma</td><td>42</td><td>24</td><td>0.357</td></tr><tr><td>&#8195;Squamous cell carcinoma</td><td>11</td><td>10</td><td/></tr><tr><td>&#8195;Others</td><td>8</td><td>7</td><td/></tr><tr><td>Tumor Stage</td><td/><td/><td/></tr><tr><td>&#8195;T1-T2</td><td>53</td><td>24</td><td>0.001*</td></tr><tr><td>&#8195;T3-T4</td><td>8</td><td>17</td><td/></tr><tr><td>Lymph node metastasis</td><td/><td/><td/></tr><tr><td>&#8195;Absent</td><td>43</td><td>25</td><td>0.318</td></tr><tr><td>&#8195;Present</td><td>18</td><td>16</td><td/></tr><tr><td>Pathological (TNM) stage</td><td/><td/><td/></tr><tr><td>&#8195;Stage I</td><td>36</td><td>14</td><td>0.014*</td></tr><tr><td>&#8195;Stage II-IV</td><td>25</td><td>27</td><td/></tr><tr><td colspan="4"><bold>B. Multivariate COX regression analysis for RFS</bold></td></tr><tr><td>Variables</td><td>P value</td><td>Hazard Ratio (HR)</td><td>95.0% CI<sup>&#8224;</sup> of HR</td></tr><tr><td>&#8195;NFATc2</td><td>0.037</td><td>1.905</td><td>1.039&#8211;3.494</td></tr><tr><td>&#8195;TNM stage</td><td>0.001</td><td>2.035</td><td>1.347&#8211;3.075</td></tr><tr><td colspan="4"><bold>C. Multivariate COX regression analysis for OS</bold></td></tr><tr><td>Variables</td><td>P value</td><td>Hazard ratio (HR)</td><td>95.0% CI<sup>&#8224;</sup> of HR</td></tr><tr><td>&#8195;NFATc2</td><td>0.002</td><td>2.824</td><td>1.462&#8211;5.457</td></tr><tr><td>&#8195;TNM stage</td><td>0.012</td><td>1.827</td><td>1.140&#8211;2.927</td></tr><tr><td>&#8195;Age</td><td>0.01</td><td>2.33</td><td>1.224&#8211;4.432</td></tr><tr><td>&#8195;Smoking history</td><td>0.009</td><td>2.416</td><td>1.251&#8211;4.665</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Statistical tests: c2; *: P&lt;0.05</p></fn><fn id="tblfn2"><p>&#8224;: Confidence Interval.</p></fn><fn id="tblfn3"><p>Statistics: COX regression analysis.</p></fn></table-wrap-foot></table-wrap>